TY - JOUR
T1 - Activation of caspase-3 in the skeletal muscle during haemodialysis
AU - Boivin, Michel A.
AU - Battah, Shadi I.
AU - Dominic, Elizabeth A.
AU - Kalantar-Zadeh, Kamyar
AU - Ferrando, Arny
AU - Tzamaloukas, Antonios H.
AU - Dwivedi, Rama
AU - Ma, Thomas A.
AU - Moseley, Pope
AU - Raj, Dominic S.C.
PY - 2010/10
Y1 - 2010/10
N2 - Background and Objective Muscle atrophy in end-stage renal disease (ESRD) may be due to the activation of apoptotic and proteolytic pathways. We hypothesized that activation of caspase-3 in the skeletal muscle mediates apoptosis and proteolysis during haemodialysis (HD). Materials and Methods Eight ESRD patients were studied before (pre-HD) and during HD and the findings were compared with those from six healthy volunteers. Protein kinetics was determined by primed constant infusion of L-(ring 13C6) Phenylalanine. Results Caspase-3 activity in the skeletal muscle was higher in ESRD patients pre-HD than in controls (24966·0 ± 4023·9 vs. 15293·3 ± 2120·0 units, P < 0·01) and increased further during HD (end-HD) (37666·6 ± 4208·3 units) (P < 0·001). Actin fragments (14 kDa) generated by caspase-3 mediated cleavage of actomyosin was higher in the skeletal muscle pre-HD (68%) and during HD (164%) compared with controls. The abundance of ubiquitinized carboxy-terminal actin fragment was also significantly increased during HD. Skeletal muscle biopsies obtained at the end of HD exhibited augmented apoptosis, which was higher than that observed in pre-HD and control samples (P < 0·001). IL-6 content in the soluble fraction of the muscle skeletal muscle was increased significantly during HD. Protein kinetic studies showed that catabolism was higher in ESRD patients during HD compared with pre-HD and control subjects. Muscle protein catabolism was positively associated with caspase-3 activity and skeletal muscle IL-6 content. Conclusion Muscle atrophy in ESRD may be due to IL-6 induced activation of caspase-3 resulting in apoptosis as well as muscle proteolysis during HD.
AB - Background and Objective Muscle atrophy in end-stage renal disease (ESRD) may be due to the activation of apoptotic and proteolytic pathways. We hypothesized that activation of caspase-3 in the skeletal muscle mediates apoptosis and proteolysis during haemodialysis (HD). Materials and Methods Eight ESRD patients were studied before (pre-HD) and during HD and the findings were compared with those from six healthy volunteers. Protein kinetics was determined by primed constant infusion of L-(ring 13C6) Phenylalanine. Results Caspase-3 activity in the skeletal muscle was higher in ESRD patients pre-HD than in controls (24966·0 ± 4023·9 vs. 15293·3 ± 2120·0 units, P < 0·01) and increased further during HD (end-HD) (37666·6 ± 4208·3 units) (P < 0·001). Actin fragments (14 kDa) generated by caspase-3 mediated cleavage of actomyosin was higher in the skeletal muscle pre-HD (68%) and during HD (164%) compared with controls. The abundance of ubiquitinized carboxy-terminal actin fragment was also significantly increased during HD. Skeletal muscle biopsies obtained at the end of HD exhibited augmented apoptosis, which was higher than that observed in pre-HD and control samples (P < 0·001). IL-6 content in the soluble fraction of the muscle skeletal muscle was increased significantly during HD. Protein kinetic studies showed that catabolism was higher in ESRD patients during HD compared with pre-HD and control subjects. Muscle protein catabolism was positively associated with caspase-3 activity and skeletal muscle IL-6 content. Conclusion Muscle atrophy in ESRD may be due to IL-6 induced activation of caspase-3 resulting in apoptosis as well as muscle proteolysis during HD.
UR - http://www.scopus.com/inward/record.url?scp=77956534016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956534016&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2362.2010.02347.x
DO - 10.1111/j.1365-2362.2010.02347.x
M3 - Article
C2 - 20636378
AN - SCOPUS:77956534016
SN - 0014-2972
VL - 40
SP - 903
EP - 910
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 10
ER -